Everyone has their own vaccine. While a large French study by Epi-Phare has confirmed the risk of myocarditis or pericarditis after vaccination against Covid-19 with a messenger RNA product (Pfizer or Moderna), the Higher Public Health Agency issued this report. a new opinion to replace the product of the American biotech Moderna in the vaccine strategy. If you are under 30 and want to protect yourself from Sars-CoV-2 this winter by getting vaccinated, then the Pfizer laboratory product should be preferred for both primary vaccination and booster dose.
Why such a change? When the vaccination campaign was rolled out to the rest of the non-priority population, namely those under 55, earlier this summer, those audiences only had a choice of two vaccines: Pfizer or Moderna. The only two messenger RNA products among the four vaccines approved in the European Union and France. Because of the risk of thrombosis in young people, vaccination with the other two products from AstraZeneca and Janssen is not recommended. Previously, the Pfizer and Moderna vaccines were considered twins because they use the same “vaccine platform,” as experts say in their scientific jargon.
But the latest study from Epi-Phare changes the situation somewhat. If she confirms the risk of myocarditis and pericarditis after vaccination with the two messenger RNA vaccines and especially in young people, slightly fewer cases would be identified at Pfizer than at Moderna. This supports the HAS recommendation to encourage the use of the Pfizer vaccine for those under 30 years of age. “But myocarditis cases are developing well, regardless of whether the patients are vaccinated with Pfizer or Moderna,” says the HAS.
Yes to the callback with Moderna … after 30 years
However, Moderna’s vaccine retains its full place in France’s vaccine strategy. But it is now aimed at those over 30 and especially the most fragile. The Haute Autorité de santé has given the green light to the use of the biotechnological vaccine from Stéphane Bancel as a vaccine booster. “Moderna’s product has been observed and confirmed to be more effective than Pfizer’s,” we tell HAS to justify the new place of the second anti-Covid messenger RNA vaccine among the most vulnerable audiences . Please note that in the case of a basic vaccination with Moderna in the full dose, the booster vaccination should be given as half the dose.
Get our latest news
Every day the choice of Main information of the day.
“Pop culture scholar. Subtly charming beer specialist. Reader. Student. Devoted music advocate.”
.jpg?w=1200&auto=format%2Ccompress&ogImage=true)
